Penumbra delivered 16.9% constant-currency revenue growth in the fourth quarter, with U.S. thrombectomy product sales up 18.5%. The performance exceeded management’s internal targets and was driven by increased procedure volume and market share gains in neurological and peripheral interventions.

In early January, Penumbra entered into a definitive agreement to be acquired by Boston Scientific for approximately $14.5 billion. The deal represents a 19% premium to Penumbra’s closing share price on the trading day before the announcement and is expected to close by mid-2026 pending regulatory approval.

The acquisition will expand Boston Scientific’s portfolio in thrombectomy and neurovascular devices, while providing Penumbra with broader global sales infrastructure. Analysts expect cost synergies through combined R&D efforts and supply chain integration, potentially boosting combined earnings per share within two years of closing.